Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Agenus Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AGEN
Nasdaq
8731
https://agenusbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Agenus Inc
Agenus Inc. (NASDAQ:AGEN) is definitely on the radar of institutional investors who own 46% of the company
- Jan 31st, 2023 11:20 am
Agenus to Participate in February Investor Conferences
- Jan 26th, 2023 12:30 pm
Agenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer Candidate
- Jan 23rd, 2023 7:33 pm
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
- Jan 23rd, 2023 12:30 pm
2 Momentum Trades Showing Worst to First Action
- Jan 18th, 2023 4:11 pm
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
- Jan 10th, 2023 1:30 pm
12 Best Biotech Stocks to Buy Under $10
- Dec 28th, 2022 3:39 pm
Agenus (NASDAQ:AGEN shareholders incur further losses as stock declines 12% this week, taking three-year losses to 42%
- Dec 21st, 2022 3:59 pm
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
- Dec 21st, 2022 1:30 pm
7 Hot Stocks to Book Profits In Before 2023
- Dec 19th, 2022 5:55 pm
Why Shares of Agenus Rose 12.5% on Friday
- Dec 2nd, 2022 9:47 pm
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
- Nov 17th, 2022 1:30 pm
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
- Nov 16th, 2022 1:30 pm
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
- Nov 14th, 2022 1:30 pm
Agenus Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
- Nov 10th, 2022 11:02 am
Agenus (AGEN) Q3 2022 Earnings Call Transcript
- Nov 8th, 2022 7:00 pm
Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
- Nov 8th, 2022 2:25 pm
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
- Nov 8th, 2022 1:00 pm
Agenus (AGEN) Dips More Than Broader Markets: What You Should Know
- Oct 31st, 2022 9:50 pm
Agenus (AGEN) to Report Q3 Earnings: What's in the Cards?
- Oct 26th, 2022 2:11 pm
Scroll